STOCK TITAN

Ainos (AIMD) Stock Price, News & Analysis

AIMD NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
71 252 sessions, November 19, 2025 to November 19, 2026
Largest daily move
+118.6% close of November 12, 2026
1-year change
-45% closing prices, November 19, 2025 to November 19, 2026
1-month change
+19.2% closing prices, October 19, 2026 to November 19, 2026

Company Description

Ainos, Inc. (NASDAQ: AIMD) is a Texas-incorporated company that has transitioned from its historical biotechnology focus into a technology-driven business centered on AI-powered digital olfaction. The company describes itself as a dual-platform AI and biotech company, combining its SmellTech platform, branded as AI Nose, with development of VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos’ shares trade on the Nasdaq Stock Market under the symbol AIMD, with associated warrants trading under AIMDW.

Ainos’ core technology platform, AI Nose, digitizes scent into Smell ID, a machine-readable data format that allows artificial intelligence systems to interpret olfactory information. The platform integrates precision MEMS sensor arrays with proprietary AI algorithms to create a full-stack electronic nose (e‑nose) system. According to company disclosures, AI Nose is designed to support parts-per-billion (ppb) level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured data, while Ainos’ Smell Language Model (SLM) is designed to classify, contextualize, and learn complex scent patterns over time.

SmellTech Platform and Dual-Engine Architecture

Ainos has articulated a dual-engine SmellTech architecture that separates the physical sensing layer from the AI intelligence layer. Within this structure, Ainos focuses on designing, manufacturing, and deploying AI Nose sensing hardware, including control over sensor design, firmware, calibration, manufacturing processes, quality assurance, and global certifications. Its wholly owned subsidiary, ScentAI Inc., operates as a pure AI software company dedicated to developing the Smell Language Model and related AI systems that transform scent data into Smell ID and higher-level intelligence.

The company states that this structural separation is intended to support scalability, governance clarity, and long-term platform durability. Ainos concentrates on physical deployment and data generation at the edge of the physical world, while ScentAI focuses on data abstraction, model training, and intelligence delivery through mechanisms such as enterprise APIs, SaaS offerings, and model licensing. The two entities are described as complementary layers within a unified SmellTech platform, rather than competitors at the product or customer level.

Commercialization Strategy and SmellTech-as-a-Service

Ainos is positioning AI Nose under a SmellTech-as-a-Service model. Company materials describe subscription-based deployment approaches that provide ongoing access to scent intelligence, analytics, and AI-driven insights. AI Nose is intended to support continuous monitoring, predictive analysis or analytics, and real-time alerts across industrial and manufacturing environments. The company has highlighted applications in semiconductor manufacturing, smart factories, robotics, healthcare, senior care, hospital infection control, and environmental monitoring, among others, where real-time environmental sensing and process stability are important.

According to Ainos’ public statements, the platform is being deployed in advanced semiconductor environments, including both back-end processes and front-end wafer fabrication. The company has entered into a distribution and deployment agreement with Trusval Technology, a Taiwan-based engineering and technical services provider specializing in semiconductor manufacturing environments. Under this agreement, Trusval serves as an authorized sales agent and deployment partner for AI Nose in defined semiconductor front-end applications, with a contractually defined initial minimum purchase commitment of 600 AI Nose units intended to support deployment in wafer fabrication facilities.

Industrial and Edge AI Partnerships

Ainos has reported an expanding ecosystem of industrial partners across semiconductors, robotics, automation, and smart manufacturing. The company has announced partnerships with firms such as NEXCOM International Co., Ltd., a provider of industrial computing and edge AI solutions. Under that collaboration, Ainos supplies AI Nose hardware and software for integration into NEXCOM’s edge AI and automation systems, with the goal of enabling real-time environmental sensing and intelligent monitoring across manufacturing and industrial applications.

Through these collaborations, AI Nose is being positioned as a scent-based edge AI solution that can process olfactory data locally at the edge rather than exclusively in the cloud. Company materials state that this approach is intended to reduce latency, support data privacy, and provide instant insights for applications such as predictive maintenance, intelligent monitoring, and sustainability-related operations. Ainos has also highlighted that its industrial ecosystem includes multiple partners in semiconductors, robotics, and smart manufacturing, and that it has showcased AI Nose modules at industry exhibitions such as SEMICON Taiwan.

Intellectual Property and Data Moat

Ainos reports a growing intellectual property portfolio around AI Nose and digital olfaction. The company has disclosed securing patents in the U.S., Europe, Germany, Japan, Taiwan, and China, and has stated that it holds 123 active patents and applications covering key technologies related to AI Nose, including product design, internal structures, system configurations, and operating principles. Recent announcements describe additional patents in Europe, Germany, Taiwan, and China that strengthen applications in robotics.

The company also emphasizes a long-term scent data moat, citing more than a decade of accumulated real-world scent data across medical, industrial, and environmental settings. This dataset underpins the training of the Smell Language Model and the development of Smell ID. Ainos presents this combination of patents and data as central to its competitive positioning in AI-powered electronic nose technologies and digital olfaction.

Sector Classification and Strategic Focus

Historically associated with biotechnology, Ainos has disclosed a Global Industry Classification Standard (GICS) reclassification to the Technology Hardware, Storage & Peripherals industry within the information technology sector. The company links this reclassification to its transformation into a technology company focused on AI-powered scent digitization and digital olfaction infrastructure. It has also referenced the establishment of a Smart Healthcare Sensing division to advance AI Nose’s healthcare applications.

Ainos continues to describe itself as a dual-platform AI and biotech company, reflecting its ongoing development of VELDONA, a low-dose oral interferon candidate targeting rare, autoimmune, and infectious diseases. In parallel, the company is building its SmellTech platform as an AI infrastructure layer intended to allow machines and industrial systems to interpret scent as a structured data language.

Corporate Structure and Headquarters

Ainos, Inc. is organized as a Texas corporation. SEC filings list the company’s principal executive offices in San Diego, California, and the company has announced plans to relocate its U.S. headquarters to Houston, Texas in early 2026. The relocation is described as a step to improve operating efficiency and to position Ainos within a technology and industrial innovation hub that aligns with its focus on advanced manufacturing, energy, healthcare, robotics, and AI.

The company has also formed ScentAI Inc. as a wholly owned subsidiary to advance its smell language model and AI software platform. ScentAI is expected to be co-located with Ainos’ headquarters to maintain close coordination between AI model development and AI Nose hardware deployed in the field.

Business Model and Revenue Approach

Ainos’ disclosures describe a business model that combines hardware deployment of AI Nose devices with software and data services enabled by ScentAI. The company has referenced SmellTech-as-a-Service subscription contracts and multi-year deployment agreements in industrial settings, including semiconductor manufacturing. It has also reported pilot programs in elderly care and senior care environments, as well as pilot deployments with a robotic partner in Japan.

According to company statements, AI Nose deployments generate continuous scent data that feeds into the Smell Language Model, creating a feedback loop in which broader deployment improves model performance, and improved models support further adoption. This feedback loop is described as a data flywheel that underlies the company’s long-term platform strategy.

Biotech Platform: VELDONA

Alongside its SmellTech activities, Ainos continues to develop VELDONA, described as a low-dose oral interferon candidate targeting rare, autoimmune, and infectious diseases. The company presents VELDONA as part of its biotech platform, complementing its AI and SmellTech initiatives. Public materials note that Ainos’ research and development spending supports both the SmellTech platform and its clinical programs, though detailed clinical results or regulatory milestones are not provided in the supplied information.

Stock Information and Governance

Ainos’ common stock trades on the Nasdaq Stock Market under the symbol AIMD, and its warrants trade under AIMDW. The company files periodic reports, proxy statements, and current reports with the U.S. Securities and Exchange Commission. A recent definitive proxy statement describes matters such as director elections, auditor ratification, and approval of special stock awards, indicating an active governance and shareholder voting process.

Stock Performance

$1.09
-1.80%
-0.02
Pre-marketLast updated: at
-45%
Performance 1 year

Ainos (AIMD) closed at $1.11 on November 19, 2026. Over the past 12 months, the price has lost 45.0%.

See what a $1,000 investment in AIMD would be worth today

Average down calculator for AIMD

AIMD Metrics & Rankings

Price returns through November 19, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Ainos has 10 recent news articles, with the latest published on . Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, AI. View all AIMD news →

Financial Highlights

Ainos generated $124K in revenue in FY2025, retaining a 82.9% gross margin, operating income reached -$14.0M, and net income was -$14.8M. Diluted earnings per share stood at -$3.46. The company generated -$4.6M in operating cash flow. The current ratio was 1.06, measuring current assets divided by current liabilities.

$124K
Revenue (FY2025)
-$14.8M
Net Income (FY2025)
-$4.6M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Financial

Convertible notes due

$11,000,000 in convertible notes mature in 2027; company has begun discussions to address repayment or restructuring.
YEAR
2027
H1
2027
H1 2027 Clinical

Veldona® 1H27 trial completion

Expected completion of Veldona® human trials in Taiwan
JAN
11
January 11, 2027 Financial

Deposit payment due

ASE to pay a $4.5M deposit to Ainos within 60 days of signing the $9M order; deadline estimated as 2027-01-11.

Ainos has 4 upcoming scheduled events. The next event, "Convertible notes due", is expected in 2027. 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the AIMD stock price.

Short Interest History

Last 12 Months

Short interest in Ainos (AIMD) currently stands at 37.5 thousand shares, down 20.3% from the previous reporting period, representing 1.1% of the float. Since November 2025, short interest has increased by 236.5%.

Days to Cover History

Last 12 Months

Days to cover for Ainos (AIMD) currently stands at 1.4 days, up 27.3% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 40%. Across the settlements charted above, it has ranged from 1.0 to 1.6 days.

AIMD Company Profile & Sector Positioning

Ainos (AIMD) operates in the Scientific & Technical Instruments industry within the broader Technology sector and is listed on the NASDAQ.

Investors comparing AIMD often look at related companies in the same sector, including Astrotech Corporation (ASTC), Focus Universal Inc. (FCUV), Odysight.ai Inc. (ODYS), Acorn Energy, Inc. (ACFN), and MIND Technology, Inc. (MIND). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate AIMD's relative position within its industry.

Frequently Asked Questions

The current stock price of Ainos (AIMD) is $1.09 in pre-market trading as of November 20, 2026.

The market cap of Ainos (AIMD) is approximately $9.5M. Learn more about what market capitalization means .

The FY2025 revenue of Ainos (AIMD) is $124K, from its most recent completed fiscal year.

The FY2025 net income of Ainos (AIMD) is -$14.8M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Ainos (AIMD) is -$3.46 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Ainos (AIMD) is -$4.6M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of Ainos (AIMD) is 82.9% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Ainos (AIMD), current assets divided by current liabilities, was 1.06 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Ainos (AIMD) is $103K for FY2025, its most recent completed fiscal year.

The operating income of Ainos (AIMD) is -$14.0M for FY2025, its most recent completed fiscal year. Learn about operating income.